BEBT-201

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameBEBT-201
Drug Alias NameBEBT-201CUDC-201
ClassificationSmall molecules
Mechanisms of ActionHistone deacetylase inhibitorsAnticancer protein kinase inhibitorsBcr-Abl tyrosine kinase inhibitors +[4] 
TargetsTyrosine-protein kinase SRCHistone deacetylaseBcr-Abl tyrosine kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesGuangzhou BeBetter Medicine Technology Co
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGuangzhou BeBetter Medicine Technology Co
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A